Phase II trial of saracatinib (AZD0530), an oral src-inhibitor for the treatment of patients with hormone receptor negative metastatic breast cancer

BACKGROUND: Src activation is associated with cell migration, proliferation and metastasis. Saracatinib is an oral, tyrosine kinase inhibitor (TKI) selective for Src. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)- and p...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Gucalp, Ayca, Sparano, Joseph A., Caravelli, James, Santamauro, Jean, Patil, Sujata, Abbruzzi, Alyson, Pellegrino, Christine, Bromberg, Jackie, Dang, Chau, Theodoulou, Maria, Massague, Joan, Norton, Larry, Hudis, Clifford, Traina, Tiffany A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2011
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3222913/
https://ncbi.nlm.nih.gov/pubmed/21729667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2011.03.021
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items